Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. (NASDAQ: CCCC) is a clinical-stage biopharmaceutical company pioneering targeted protein degradation therapies for cancer and other challenging diseases. This news hub provides investors and industry professionals with timely updates on the company's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases, clinical trial progress reports, and partnership announcements in one centralized location. Our curated collection includes updates on key pipeline assets like cemsidomide and CFT1946, collaboration developments with Biogen and Merck, and financial disclosures essential for informed decision-making.
Discover comprehensive coverage of C4 Therapeutics' innovative TORPEDO® platform advancements, protein degrader research breakthroughs, and participation in major medical conferences. All content is sourced directly from company filings and verified industry publications to ensure accuracy.
Bookmark this page to stay informed about CCCC's progress in developing novel therapies that address drug resistance and undruggable targets through targeted protein degradation science. Check regularly for new developments in this cutting-edge area of biopharmaceutical research.
C4 Therapeutics, Inc. (Nasdaq: CCCC), a clinical-stage biopharmaceutical company, announced its participation in a fireside chat at the Stifel 2023 Virtual Targeted Oncology Days. The event is scheduled for April 26, 2023, at 11:00 AM ET. C4T is focused on advancing targeted protein degradation science to develop small-molecule medicines aimed at transforming disease treatment. Through its innovative TORPEDO® platform, C4T is designing therapies that leverage the body’s protein recycling system to degrade disease-causing proteins, addressing challenges like drug resistance. A live webcast of the chat will be available on C4T's website, along with an archived replay for 30 days post-event.
C4 Therapeutics (Nasdaq: CCCC) reported a revenue decline to $31.1 million for the year ended December 31, 2022, down from $45.8 million in 2021, primarily due to a one-time recognition in the prior year. R&D expenses increased to $117.8 million from $94.7 million, driven by clinical activities. The company posted a net loss of $128.2 million and net loss per share of $2.62, compared to $83.9 million and $1.82, respectively. Despite the financial challenges, C4T anticipates a cash runway until the end of 2024 and is focusing on advancing multiple clinical trials, with important data expected in 2H 2023.
C4 Therapeutics, Inc. (Nasdaq: CCCC), a clinical-stage biopharmaceutical firm, announced its participation in two virtual conferences in February 2023. The SVB Securities Global Biopharma Conference will feature a fireside chat on February 15 at 3:00 PM ET, while a panel discussion titled Key Targets for Targeted Protein Degradation in Oncology is scheduled for February 21 at 12:00 PM ET during the 2023 Wells Fargo Targeted Protein Degradation Summit. Live webcasts will be accessible on the company’s website, with archived replays available for 30 days. C4T is focused on targeted protein degradation to develop innovative therapies for challenging diseases.
